Soundbites: Cost-Effectiveness Analysis
Scan brief descriptions of cost-effectiveness analyses conducted by our center community and our decision science colleagues across the globe.
Scaling Cancer Prevention
This analysis used decision analytic modeling to estimate the health impact, costs, and cost-effectiveness of scaling-up HPV vaccination and cervical cancer screening in 50 low- and lower-middle-income countries.
Investment Case for TB Vaccines
CHDS postdoctoral fellow Allison Portnoy and CHDS faculty Nick Menzies led economic analyses for a World Health Organization (WHO) report that describes the full value proposition for new tuberculosis (TB) vaccines.
Cost-Effectiveness Thresholds
Interventions that impose costs per DALY averted less than 3x and 1x GDP per capita are considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of this threshold.
A Monte Carlo simulation model of the natural history of HPV infection and cervical cancer was empirically calibrated to epidemiological data in Nicaragua. After integrating country-specific data on screening costs and test performance, the cost-effectiveness of alternative cervical cancer screening strategies was evaluated.
Immunization policymakers at global and local levels need to establish priorities among new vaccines competing for limited resources. This study provides early insight into how the comparative impact of two new vaccines could be assessed in resource-poor settings with respect to affordability, cost-effectiveness, and distributional equity.